191 related articles for article (PubMed ID: 22466331)
1. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.
Ortenberg R; Sapir Y; Raz L; Hershkovitz L; Ben Arav A; Sapoznik S; Barshack I; Avivi C; Berkun Y; Besser MJ; Ben-Moshe T; Schachter J; Markel G
Mol Cancer Ther; 2012 Jun; 11(6):1300-10. PubMed ID: 22466331
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
Markel G; Seidman R; Stern N; Cohen-Sinai T; Izhaki O; Katz G; Besser M; Treves AJ; Blumberg RS; Loewenthal R; Mandelboim O; Orenstein A; Schachter J
J Immunol; 2006 Nov; 177(9):6062-71. PubMed ID: 17056532
[TBL] [Abstract][Full Text] [Related]
3. The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro.
Dupuis ML; Fiori V; Soriani A; Ricci B; Dominici S; Moricoli D; Ascione A; Santoni A; Magnani M; Cianfriglia M
J Immunother; 2015; 38(9):357-70. PubMed ID: 26448580
[TBL] [Abstract][Full Text] [Related]
4. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells.
Zaffran I; Landolina N; Gaur P; Rovis TL; Jonjic S; Mandelboim O; Singer BB; Levi-Schaffer F
Cancer Gene Ther; 2022 Nov; 29(11):1676-1685. PubMed ID: 35681020
[TBL] [Abstract][Full Text] [Related]
5. CEACAM1 promotes melanoma cell growth through Sox-2.
Ortenberg R; Galore-Haskel G; Greenberg I; Zamlin B; Sapoznik S; Greenberg E; Barshack I; Avivi C; Feiler Y; Zan-Bar I; Besser MJ; Azizi E; Eitan F; Schachter J; Markel G
Neoplasia; 2014 May; 16(5):451-60. PubMed ID: 24931667
[TBL] [Abstract][Full Text] [Related]
6. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
[TBL] [Abstract][Full Text] [Related]
7. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation.
Kammerer R; Stober D; Singer BB; Obrink B; Reimann J
J Immunol; 2001 Jun; 166(11):6537-44. PubMed ID: 11359805
[TBL] [Abstract][Full Text] [Related]
9. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.
Kammerer R; Riesenberg R; Weiler C; Lohrmann J; Schleypen J; Zimmermann W
J Pathol; 2004 Nov; 204(3):258-67. PubMed ID: 15476270
[TBL] [Abstract][Full Text] [Related]
10. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.
Markel G; Seidman R; Cohen Y; Besser MJ; Sinai TC; Treves AJ; Orenstein A; Berger R; Schachter J
Immunology; 2009 Feb; 126(2):186-200. PubMed ID: 18557789
[TBL] [Abstract][Full Text] [Related]
11. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
13. Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T lymphocyte function.
Nakajima A; Iijima H; Neurath MF; Nagaishi T; Nieuwenhuis EE; Raychowdhury R; Glickman J; Blau DM; Russell S; Holmes KV; Blumberg RS
J Immunol; 2002 Feb; 168(3):1028-35. PubMed ID: 11801635
[TBL] [Abstract][Full Text] [Related]
14. Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.
Ortenberg R; Sapoznik S; Zippel D; Shapira-Frommer R; Itzhaki O; Kubi A; Zikich D; Besser MJ; Schachter J; Markel G
J Immunol Res; 2015; 2015():902137. PubMed ID: 26688824
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.
Stern N; Markel G; Arnon TI; Gruda R; Wong H; Gray-Owen SD; Mandelboim O
J Immunol; 2005 Jun; 174(11):6692-701. PubMed ID: 15905509
[TBL] [Abstract][Full Text] [Related]
16. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.
Sapoznik S; Ortenberg R; Schachter J; Markel G
Curr Top Med Chem; 2012; 12(1):3-10. PubMed ID: 22196267
[TBL] [Abstract][Full Text] [Related]
17. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells.
Markel G; Gruda R; Achdout H; Katz G; Nechama M; Blumberg RS; Kammerer R; Zimmermann W; Mandelboim O
J Immunol; 2004 Sep; 173(6):3732-9. PubMed ID: 15356119
[TBL] [Abstract][Full Text] [Related]
18. Systemic dysregulation of CEACAM1 in melanoma patients.
Markel G; Ortenberg R; Seidman R; Sapoznik S; Koren-Morag N; Besser MJ; Bar J; Shapira R; Kubi A; Nardini G; Tessone A; Treves AJ; Winkler E; Orenstein A; Schachter J
Cancer Immunol Immunother; 2010 Feb; 59(2):215-30. PubMed ID: 19633846
[TBL] [Abstract][Full Text] [Related]
19. CEACAM1 structure and function in immunity and its therapeutic implications.
Kim WM; Huang YH; Gandhi A; Blumberg RS
Semin Immunol; 2019 Apr; 42():101296. PubMed ID: 31604530
[TBL] [Abstract][Full Text] [Related]
20. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.
Fantini M; David JM; Annunziata CM; Morelli MP; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2020 Apr; 35(3):190-198. PubMed ID: 31928422
[No Abstract] [Full Text] [Related]
[Next] [New Search]
